ArticleJournal of neurointerventional surgery2026
CYP2C19 genotype-guided antiplatelet therapy to prevent thromboembolic events after stent-assisted coil embolization of unruptured intracranial aneurysms: a retrospective cohort study.
Article in Journal of neurointerventional surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCYP2C19 genotyping has been widely studied to guide antiplatelet therapy in cardiovascular disease; however, its role in neurointerventional procedures, particularly for unruptured intracranial aneurysms (UIA), remains underexplored. This study aimed to evaluate the clinical utility of CYP2C19-guided antiplatelet therapy following stent-assisted coil embolization (SAC) in patients with UIA.
methodsA total of 403 patients who underwent SAC were included. The control group (n=220) received standard dual antiplatelet therapy (DAPT) with aspirin and clopidogrel, without genotyping. The genotype-guided group (n=183) received personalized DAPT based on the CYP2C19 metabolizer status. The primary outcome was the occurrence of intracranial ischemic events within 90 days of surgery. The secondary outcomes included systemic hemorrhagic events.
resultsIntracranial ischemic events occurred in 33 patients: 24 (10.9%) in the control group and 9 (4.9%) in the genotype-guided group, representing a relative risk reduction of 54.9% (P=0.029). Systemic hemorrhagic events were reported in 22 patients: 10 (4.5%) in the control group and 12 (6.6%) in the genotype-guided group, with no statistically significant difference (P=0.388).
conclusionCYP2C19-guided antiplatelet therapy significantly reduces the risk of intracranial ischemic events after SAC in patients with UIA without increasing systemic bleeding complications. This genotype-based approach may enhance the safety and efficacy of perioperative management of neurointerventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.